StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis

Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.

NCT Number	NCT06767150
Lead Sponsor	University Hospital, Toulouse
Conditions	Postmenopausal Osteoporosis
Enrollment	200 participants
Start Date	2025-10-02
Primary Completion	2030-10 (estimated)
Study Completion	2030-10 (estimated)
Updated on ClinicalTrials.gov	2025-12-31